Drug Profile
Research programme: monoclonal antibody therapeutics - Integral Molecular/Ligand Pharmaceuticals
Alternative Names: MPS Discovery Engine™ - Integral MolecularLatest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Crystal Bioscience; Integral Molecular
- Developer Integral Molecular
- Class Analgesics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Pain in USA (Parenteral)
- 28 Apr 2020 Early research development is ongoing in USA
- 16 Nov 2012 Early research in Undefined indication in USA (Parenteral)